The final portion of the biologics license application (BLA) submission includes all of the clinical safety and efficacy data generated from studies of ATryn, including the pivotal study
Under the terms of the agreement, Roche will provide a $10 million upfront payment. In the event a development candidate is identified, Roche will assume development responsibility, and
The panel of markers being acquired by Miraculins has shown evidence of its ability to diagnose the disease in its earliest stages. According to Miraculins, a reliable test
The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in
The Phase IIa randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety and tolerability of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in 48
Mr Pascoe succeeds David Hale, who has served as Somaxon’s interim CEO since January 2008. Mr Hale will continue as the company’s executive chairman of the board. Prior
These agreements establish IPC’s operations in two additional northeastern states, expanding its national presence to 18 states. Skip Strauchman, regional executive director of IPC, said: “With our expansion
Medicsight’s ColonCAD computer-aided detection technology aims to assist radiologists in the detection of colorectal neoplasia by automatically highlighting suspicious areas on computed tomography colonography scan images. The software
Juanita Hinshaw, independent member of the board of directors, said: “As a founder of Synergetics and as its CEO, Gregg was instrumental in successfully implementing the company’s growth
Mr Moreadith will lead clinical drug development, clinical pharmacology and toxicology, and regulatory affairs at Nektar. He is responsible for overseeing all aspects of drug development at the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.